View in EDS

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.

Saved in:
Bibliographic Details
Title: Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Authors: Saad, Fred1 fred.saad@umontreal.ca, Carles, Joan2, Gillessen, Silke3, Heidenreich, Axel4, Heinrich, Daniel5, Gratt, Jeremy6, Lévy, Jérémy7, Miller, Kurt8, Nilsson, Sten9, Petrenciuc, Oana10, Tucci, Marcello11, Wirth, Manfred12, Federhofer, Judith13, O'Sullivan, Joe M14,15, O'Sullivan, Joe M16 (AUTHOR), Radium-223 International Early Access Program Investigators (CORPORATE AUTHOR)
Source: Lancet Oncology. Sep2016, Vol. 17 Issue 9, p1306-1316. 11p.
Database: Academic Search Ultimate
Description
ISSN:14702045
DOI:10.1016/S1470-2045(16)30173-5